Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,701–1,800 of 3,116
Cardiology: What You May Have Missed in 2023
Alfraih, A., Tago, A., LaCombe, M. A., & Kussmaul, W. G. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0581 · Cited by 2
Unraveling the Link Between Aortic Stenosis and Atherosclerosis: What Have We Learned?
Cinezan, C., Rus, C. B., & Ilias, I. T. (2025) · Medicina · doi:10.3390/medicina61081375 · Cited by 4
Eroglu, T. E., Coronel, R., Folke, F., & Gislason, G. (2024) · Resuscitation Plus · doi:10.1016/j.resplu.2024.100821 · Cited by 3
Horn, D. B., Shukla, A. P., Huang, H., Twum, E. A., Allen, S. E., & Kiš, S. G. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100301 · Cited by 2
“…efficacy in adults without a specific focus on age groups, and limited data are available on the use of incretin-based medications in older adults [20 – 23] who may be more likely to have multiple chronic conditions and polypharmacy, increasing the risk of medication-related problems [24,25].”
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
“245,246 Beyond metabolic and cardio-renal domains, emerging evidence points to potential disease-modifying effects of GLP-1RAs in degenerative musculoskeletal conditions, likely mediated through attenuation of chronic meta-inflammation.”
Xanthopoulou, M., Evangelidis, P., Poulis, D., Gavriilaki, E., Kotsiou, N., Antza, C., Kotsis, V., Doxani, C., Mprotsis, T., Zintzaras, E., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19030462 · Cited by 2
Divya, A., Dalal, N., Yoshida, Y., Kanwar, M. K., Catarino, P., & DʼAlessandro, D. A. (2026) · ASAIO Journal · doi:10.1097/mat.0000000000002804 · Cited by 1
Zbârcea, C. E., Marineci, C., Valeanu, A., Chiriţă, C., & Șeremet, O. C. (2026) · Diabetology · doi:10.3390/diabetology7060108 · Cited by 3
“Evidence shows reduced major cardiovascular events and mortality in T2DM, with semaglutide also lowering cardiovascular risk in overweight or obese patients without diabetes [126].”
Deng, L., Tighiouart, H., Oka, T., et al. (2025) · medRxiv · doi:10.1101/2025.05.19.25327963 · Cited by 1
Managing Obesity in Individuals with Cardiovascular Disease: Are We Missing the Obvious?
Gao, M., Kurala, T. S., & Ajjan, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.53 · Cited by 1
“26,41 Recent mechanistic and clinical studies further support decreases in high-sensitivity C-reactive protein and pro-atherogenic lipid species, enhanced microvascular perfusion, and attenuation of postprandial triglyceride excursions.”
Pasqua, M., Doumat, J., Tsoukas, M. A., & Haidar, A. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.10.175 · Cited by 1
Acuña, P., ALBHAISI, O. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Díaz, L. A., & Arab, J. P. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.61 · Cited by 2
Joy, E., & Bonnet, J. P. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261450530 · Cited by 1
Epicardial adipose tissue in diabetic myocardial disorder: Role of echocardiography
Čokljat, A. Đ., Rotkvić, P. G., Čokljat, D., Ferri-Certić, J., & Babić, Z. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i10.107640 · Cited by 2
Liuzzo, G., Greene, S. J., Mendieta, G., & Fordyce, C. B. (2026) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2026.06.001 · Cited by 2
Bloomgarden, Z. T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13568 · Cited by 1
Obesity in Spain: an open book that must be read
de Victoria, E. O. M., Vila, A. P., & Pineda, A. J. (2024) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2024.03.015 · Cited by 2
The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy
Shestakova, M. V., & Bashlykova, R. O. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.10.203366 · Cited by 6
Wilson, L. M., & Anderson, T. S. (2025) · Neurology · doi:10.1212/wnl.0000000000213739 · Cited by 1
Efficacy of Tirzepatide for Weight Loss in China: Implications for the Global Obesity Epidemic
Qian, F., & Hu, F. B. (2024) · JAMA · doi:10.1001/jama.2024.7928 · Cited by 1
Does Our Classification System for CKD Serve the US Population Well?
Kattah, A. G., & Rule, A. D. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000433 · Cited by 1
Hamayal, M., Akhtar, C. H., Ahmad, N., Awwab, M., Shahid, W., Abbasi, H. S., Nadeem, E., Siddiqui, E., Zafar, W., & Hussain, S. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00727-y · Cited by 1
Alati, A., Scher, N., & Tolédano, A. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10691-1 · Cited by 1
Hasan, I., Bessette, L. G., Jacquemyn, X., Wang, Y., subramaniam, K., Hasan, Z., Thoma, F. W., Ogami, T., Bonatti, J. O., Kaczorowski, D., et al. (2026) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2026.02.005 · Cited by 2
Cardiovascular risk management in the elderly: a dilemma in daily clinical practice
Dacquino, G. M., Galati, G., Genovese, L., Bravo, F. F., Bernardi, M., Spadafora, L., & Pedretti, R. F. E. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag316 · Cited by 1
Banack, H. R., Platt, R. W., & Matthay, E. C. (2024) · Current Epidemiology Reports · doi:10.1007/s40471-024-00353-3 · Cited by 1
Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis
Abdul-Aziz, O., Leașu, G. F., Badea, M., Constantinescu, M., Vârciu, M., & Rogozea, L. M. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002156 · Cited by 2
US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes
Karthikeyan, H., Fan, W., & Wong, N. D. (2025) · Diabetes and Vascular Disease Research · doi:10.1177/14791641251376551 · Cited by 1
Theodorakopoulou, M. P., Miglinas, M., & Jørgensen, M. B. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae207 · Cited by 2
Efficacy and safety of semaglutide in patients with heart failure: A meta-analysis
Li, X., Liu, G., & Liu, Y. (2025) · Precision medication. · doi:10.1016/j.prmedi.2025.100064 · Cited by 1
Increased Risk of Infections in People Living With Diabetes
Critchley, J., Carey, I. M., Chaudhry, U. A. R., Bowen, L., Cook, D. G., & Harris, T. (2026) · Diabetes · doi:10.2337/dbi26-0004 · Cited by 1
Wu, A., Wu, Y., Song, M., Chen, W., Xu, K., Wu, M., & Lin, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-13014-2 · Cited by 3
Targeting fibrosis and steatohepatitis through the metabolism – results from the ESSENCE trial
Michel, M. S., & Schattenberg, J. M. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101492 · Cited by 3
Cardiometabolic and Diabetes Management in Older Adults
Marion, W., & Neeland, I. J. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.005 · Cited by 1
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?
Keedy, C. A., & Bland, C. M. (2024) · JAAPA · doi:10.1097/01.jaa.0000000000000017 · Cited by 1
Shuey, T. C., Voyce, S. J., Jones, L. K., Johns, A. M., deRichemond, C., LeMaire, S. A., Lagerman, B., & Agarwal, S. (2024) · medRxiv · doi:10.1101/2024.09.08.24313086 · Cited by 2
Impact of a dermatological rehabilitation program on cardiovascular risks of psoriasis patients
Attar, J. A., von Martial, S., Troost, K., Neumeister, T., Ehrchen, J. M., Steinbrink, K., Muke, J., & Tsianakas, A. (2024) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15585 · Cited by 1
Obésité et risque cardiovasculaire
Paillard, F. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.06.001 · Cited by 1
Weight-loss-independent actions of GLP-1 medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.07.006 · Cited by 4
Brenisin, K., Kinnafick, F., King, J. A., Millard, L., Arya, D., Hodgson, E., Huggins, M., Simmons-Roberts, A., O'Dowd, M., Rayment, N., et al. (2025) · JMIR Research Protocols · doi:10.2196/76013 · Cited by 1
“In addition to reduced weight, treatment with semaglutide also significantly improved waist circumference, cardiovascular functioning, and physical functioning compared to placebo [34].”
Fan, Y., Chen, X., Cai, X., Dong, Y., Liu, C., Chen, Y., Lip, G. Y. H., & Zhu, W. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156678 · Cited by 1
Kwaah, P. A., Mensah, S., Carboo, A. K., Rashid, H. A., Agyemang, E. A., Appah, G., & Frimpong, S. K. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101857 · Cited by 1
Cardiovascular Science, Medicine, and Society: The Brave New World
Regan, J. A., Laitner, M. H., & Dzau, V. J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.085 · Cited by 3
Ramos, M., Larsen, S., Fusco, F., Lamotte, M., & Capehorn, M. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2575692 · Cited by 3
“For recurrent CVD events in patients without diabetes, risk equations were developed based on the SELECT trial 17,18 .”
GLP-1 receptor agonists should be rigorously tested as longevity therapeutics
Marino, N., Fiore, M., & Zhavoronkov, A. (2026) · Nature Health · doi:10.1038/s44360-026-00109-x · Cited by 1
Lim, M. Y., Allahwala, M. A., Booth, A. E. C., Evans, S., Jesudason, D. R., Marathe, J., Psaltis, P. J., & Nelson, A. J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.008 · Cited by 1
Neuropsychiatric side effects of semaglutide in patients with dementia
Jamshed, N., Rehman, S. T., & Khan, N. (2025) · BMJ Case Reports · doi:10.1136/bcr-2024-262743 · Cited by 1
Kuo, N. I.-H., Hill, F. R., Arnott, C. G., Douglas, K. A., Barbieri, S., Ferdousi, S., Gandomkar, Z., Luxan, B. G., Woodward, M., & Jorm, L. R. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.09.012 · Cited by 1
Maki, K. C., Kirkpatrick, C. F., & Almandoz, J. P. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.019 · Cited by 1
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
Reversal of inflammatory reprogramming by vasodilator agents in pulmonary hypertension
Kirillova, A., Sethuraman, M., Dong, X., Kirdar, A., Speyer, G., Aaraj, Y. A., Watson, A. M. M., Schneider, L. K., Creager, M. D., Lafyatis, R., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00486-2024 · Cited by 2
Reddy, Y. N. V., & Sundaram, V. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3380 · Cited by 1
Park, A. K., Hom, J., Lorenzo, J., Rao, V. K., Hui, G., Vickers, M., & Ahuja, N. K. (2025) · Journal of Hospital Medicine · doi:10.1002/jhm.70228 · Cited by 2
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes · doi:10.2337/dbi24-0046 · Cited by 1
Self-citationMetabolic Liver Disease Beyond the Liver
Gastaldelli, A., Tacke, F., & Holleboom, A. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.003 · Cited by 1
Vahtera, V., Pajarinen, J., Kivimäki, M., Ervasti, J. M., Pentti, J., Stenholm, S., Vahtera, J., & Salminen, P. T. P. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000003993 · Cited by 2
Lee, R. S. M., Seah, J., Baqar, S., Srivastava, P., Levelt, E., Leet, A. S., MacIsaac, A. I., Ekinci, E. I., & MacIsaac, R. J. (2026) · Medicina · doi:10.3390/medicina62050870 · Cited by 2
“Of note, and as mentioned previously, GLP-1-based medications increase the heart rate via still poorly understood mechanisms, with most studies reporting an increase of approximately 2–4 beats per min [22,26].”
Saraiya, V., Fung, T. T., Pitts, S. J., Wu, Q., Berkowitz, S. A., Skinner, H. G., Thaxton, C. K., Alick, C. L., Sotres‐Alvarez, D., Evenson, K. R., et al. (2025) · Nutrition and Health · doi:10.1177/02601060251379522 · Cited by 1
Interventions to prevent or treat obesity in adult Indigenous Australians: A systematic review
Lan, N. S. R., Ford, J., Gregory, L., Jones, G., Dwivedi, G., & Yeap, B. B. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.04.003 · Cited by 1
Franco, J. V. A., Hindemit, J., Guo, Y., Bongaerts, B. W. C., Metzendorf, M., Peelen, R., Køster‐Rasmussen, R., Meyer, L. B., Noyes, J., & Möhler, R. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016107 · Cited by 3
As, A., Beliy, P. A., Zaslavskaya, K. Y., Rogozhina, E. A., Shcherbakova, V. S., Kazaishvili, Y. G., Таганов, А. В., Геннадьевна, Б. Т., Mishchenko, E. S., Koryanova, K. N., et al. (2025) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2024-12-3-231-246 · Cited by 3
Vignarajah, A., Oro, P., Dahdah, J. E., Vigneswaramoorthy, N. A., Vest, A. R., & Shah, G. V. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100676 · Cited by 5
“The SELECT trial demonstrated reductions in cardio-vascular mortality and heart failure endpoints with Semaglutide in patients with established cardiovascular disease [3].”
InfluentialThe effect of weight change on death and cardiovascular events after Roux-en-Y gastric bypass
Stenberg, E., Näslund, E. B., Cao, Y., Ottosson, J., & Näslund, I. (2025) · British journal of surgery · doi:10.1093/bjs/znaf170 · Cited by 1
Janssen, S., Woelders, E. C. I., Peeters, D. A. M., Winkler, P. J. C., Damman, P., Remkes, W. S., Luijkx, J. J. P., Merry, A. H. H., Rasoul, S., van Geuns, R. J. M., et al. (2026) · Diabetology · doi:10.3390/diabetology7020025 · Cited by 1
Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial
Colhoun, H. M., Lincoff, A. M., Ryan, D. H., Lingvay, I., Kahn, S. E., Hovingh, G. K., Hardt‐Lindberg, S., Oral, T. K., Weeke, P. E., Linder, M., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag524 · Cited by 7
Self-citationPragati, G., Pozzilli, V., Giovanni, A. D., Sapio, E., Motolese, F., Capone, F., & Pozzilli, P. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70246 · Cited by 3
“30 Dedicated stroke trials have also reported prelimi-nary vascular signals: liraglutide reduced recurrent stroke in the LAMP trial of minor ischaemic stroke or high-risk TIA with type 2 diabetes, 36 while semaglutide was safe in the GALLOP phase 2 large-vessel occlusion trial and showed benefit in…”
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
“…the SELECT study demonstrated a 20% decrease in serious adverse cardiovascular events in people with preexisting cardiovascular illness but no diabetes, semaglutide still maintains a significant advantage in cardiovascular outcomes until we have a better understanding of the SURPASS-CVOT [6].”
InfluentialTargeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies
Spindler, M. P., Libby, P., & Ridker, P. M. (2026) · Immunological Reviews · doi:10.1111/imr.70151 · Cited by 4
“Similarly, the LEADER, SUSTAIN-6, and SELECT trials have established the cardiovascular benefits of incretin-based therapies in patients with and without diabetes [79–81].”
Obesity in Cardiorenal syndrome: Management Opportunities and Challenges
Reaves, A. C., Jaffe, E., & McCallum, W. I. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01352-5 · Cited by 1
“[ 43 ].”
Busk‐Cirera, L., Carlsen, I. Ø., Madsen, L. B., Sandsdal, R. M., Jensen, E., Jensen, S. B. K., & Torekov, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71006 · Cited by 6
“Overweight and obesity are associated with numerous health complications, including cardiovascular diseases [2], type 2 diabetes [3], cancers [4], and digestive diseases [5].”
Kjærgaard, J., Møller, C. H., Wiberg, S. C., et al. (2024) · medRxiv · doi:10.1101/2024.10.15.24315567 · Cited by 1
Kumar, A., Scroggie, S., Sarkar, T. D., Hepokoski, M., & Malhotra, A. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2561067 · Cited by 1
The recent renewed interest among cardiologists in detecting and preventing diabetes is welcomed
Norhammar, A., & Ritsinger, V. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae833 · Cited by 2
Generalizability of SELECT to Cardiac Surgical Patients
Dhingra, N. K., Verma, R., Mazer, C. D., & Verma, S. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101597 · Cited by 1
Powell, W. J. B., Mazzotti, D. R., Herrmann, S. D., Davis, A. M., Mittendorfer, B., Bruce, J. M., Song, X., & Waitman, L. R. (2026) · Clinical Obesity · doi:10.1111/cob.70076 · Cited by 1
Moll, H., Puhan, M. A., Gerber, P. A., Beuschlein, F., Frenes, K., Spanu, A., Walter, J. E., & Yebyo, H. G. (2025) · medRxiv · doi:10.64898/2025.12.15.25342259 · Cited by 2
Khan, M. Q., Becchetti, C., Jouid, M. R., Mortuza, R., Panda, S., Pierluissi, V., Stegagnini, M., Punchhi, G., Bajunayd, A., Viganò, R., et al. (2026) · Liver Transplantation · doi:10.1097/lvt.0000000000000917 · Cited by 2
Preoperative Telerehabilitation Improves Outcomes After Cardiac Surgery
Verma, S., Mori, M., & Gaudino, M. F. L. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.031 · Cited by 1
Katsura, M., Horiuchi, Y., Tanabe, K., & Wettersten, N. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70721 · Cited by 1
“Subcutaneous sema-glutide has been shown to reduce major adverse cardiovascular events (MACE) in individuals with established ASCVD, with or without T2DM [4, 5].”
Pharmakotherapie der Adipositas
Roser, P. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01167-z · Cited by 1
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615i · Cited by 2
Medicatie voor obesitas: vooruitgang en uitdagingen
Muskiet, M. H. A., & Boon, M. R. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1569-4 · Cited by 1
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
“In individuals with overweight or obesity and established CV disease without diabetes, once-weekly (QW) subcutaneous (SC) semaglutide 2.4 mg reduced MACE in the SELECT trial [11].”
InfluentialWeighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.
Thomas, T. S., & Srinivasa, S. (2024) · PubMed Central · Cited by 7
Adiposity-Based Chronic Disease
Garvey, W. T. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_2 · Cited by 1
Mahmod, M., Dennis, A., Lian, J., Langford, C., Rahimi, K., & Wamil, M. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10629-z · Cited by 2
From the SELECT study to SOUL: different administration methods of semaglutide but same efficacy?
Gatto, L., Biccirè, F. G., Lentini, A. E., Scalia, L., & Prati, F. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf024 · Cited by 2
Single-cell genetics identifies cell-type-specific effector genes across complex traits and diseasesPreprint
Henry, A., Senabouth, A., Tyebally, M., Bowen, B., Allen, P. C., Spenceley, E., Sagi-Zsigmond, E., McCloy, R. A., Cuomo, A. S. E., Fan, J., et al. (2025) · medRxiv · doi:10.1101/2025.08.28.25334614 · Cited by 5
Corbalan, J. J., Petronella, B. A., Huang, C., Beasley, J. R., Merritt, J. R., Mugrage, B., & Nickels, J. T. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152360 · Cited by 1
Liuzzo, G., & Patrono, C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae076 · Cited by 1
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
Lee, J., You, J. H., Park, H. J., Roh, J.-L., & Paek, S. H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00709-4 · Cited by 3
“Reported or emerging application areas include joint disorders [33, 34], psychotic and neurocognitive conditions [35], cardiovascular disease [36], and gastrointestinal disorders [37 – 39].”
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF
Kamat, I., & Nair, A. P. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012432 · Cited by 1
Association of GLP-1 agonists with metabolic and acid–base disorders after radical cystectomy
Manivasagam, S. S., Ahmad, N. B., Kassim, A., & Raman, J. D. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.03.008 · Cited by 1
Abdallah, H., Khalil, M., Mahdi, L., Pietragalla, G., Faienza, M. F., Garruti, G., & Portincasa, P. (2026) · Nutrients · doi:10.3390/nu18142317 · Cited by 1
“…superiority trial was conducted on 17,604 patients with established atherosclerotic cardiovascular disease and clinical obesity, where 8803 received 2.4 mg semaglutide for approximately 40 months, showing a statistically superior 20% relative risk reduction in MACE in the semaglutide group [269].”
InfluentialKaur, R., & Singh, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71031 · Cited by 1
“The cardiorenal pleiotropic mechanisms of GLP-1 RAs operate through multiple interconnected pathways partially independent of glycaemic control, as substantiated by SELECT trial data demonstrating MACE reduction (HR 0.80, 95% CI 0.72–0.90) in non-diabetic individuals with obesity [21].”
InfluentialThe ABCs of cardiovascular disease prevention: communicating what we know in 2026
Goren, L. R., Peng, A. W., Razavi, A. C., Blaha, M. J., Blumenthal, R. S., & Troy, A. L. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101570 · Cited by 2
Kandalam, S., Benamar, M., Reun, C. L., Rengger, L., Gupta, P., & Nair, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01847-7 · Cited by 1
“…with IDegLira, which is in line with evidence from recent NMAs [2, 35] and semaglutide cardiovascular outcome trials (SUSTAIN 6, SOUL, and FLOW [36–38]), and supports GLP-1 RAs as effective therapy for patients requiring basal insulin intensification, with demonstrated cardiovascular and renal…”
Störk, S., & Nitschmann, S. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01932-2 · Cited by 1
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
